Details for Patent: 10,035,822
✉ Email this page to a colleague
Which drugs does patent 10,035,822 protect, and when does it expire?
Patent 10,035,822 protects SYFOVRE and EMPAVELI and is included in two NDAs.
This patent has forty-nine patent family members in twenty-four countries.
Summary for Patent: 10,035,822
| Title: | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
| Abstract: | Long-acting compstatin analogs comprising a clearance-reducing moiety attached to two compstatin analog moieties, each compstatin analog moiety comprising a cyclic peptide extended by a lysine residue or a sequence comprising a lysine residue at the N-terminus, C-terminus, or both, wherein the lysine residue is separated from the cyclic portion of the peptide by a rigid or flexible spacer comprising an oligo(ethylene glycol) moiety, the clearance reducing moiety comprises a linear polymer, wherein each end of the linear polymer is linked to one of the compstatin analog moieties by way of a carbamate, wherein (i) the spacer comprises --(CH2).sub.m-- and --(O--CH2-CH2--).sub.n joined covalently, wherein m is between 1 and 10 and n is between 1 and 10; and/or (ii) the spacer comprises 8-amino-3,6-dioxaoctanoic acid (AEEAc) or 11-amino-3,6,9-trioxaundecanoic acid. |
| Inventor(s): | Francois; Cedric (Louisville, KY), Deschatelets; Pascal (Louisville, KY) |
| Assignee: | Apellis Pharmaceuticals, Inc. (Crestwood, KY) |
| Application Number: | 14/443,143 |
|
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 10,035,822
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharms | SYFOVRE | pegcetacoplan | SOLUTION;INTRAVITREAL | 217171-001 | Feb 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Apellis Pharms | EMPAVELI | pegcetacoplan | SOLUTION;SUBCUTANEOUS | 215014-001 | May 14, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,035,822
| PCT Information | |||
| PCT Filed | November 15, 2013 | PCT Application Number: | PCT/US2013/070417 |
| PCT Publication Date: | May 22, 2014 | PCT Publication Number: | WO2014/078731 |
International Family Members for US Patent 10,035,822
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3660033 | ⤷ Sign Up | 301178 | Netherlands | ⤷ Sign Up |
| European Patent Office | 3660033 | ⤷ Sign Up | PA2022010 | Lithuania | ⤷ Sign Up |
| European Patent Office | 3660033 | ⤷ Sign Up | 2022C/522 | Belgium | ⤷ Sign Up |
| European Patent Office | 3660033 | ⤷ Sign Up | CA 2022 00023 | Denmark | ⤷ Sign Up |
| European Patent Office | 3660033 | ⤷ Sign Up | LUC00265 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 3660033 | ⤷ Sign Up | 122022000034 | Germany | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
